

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT																				
NATURE OF CONVEYANCE:	NUNC PRO TUNC ASSIGNMENT																				
EFFECTIVE DATE:	06/01/2004																				
CONVEYING PARTY DATA																					
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>F. Timothy Guilford</td> <td>01/09/2012</td> </tr> <tr> <td>Brian C. Keller</td> <td>01/09/2012</td> </tr> </tbody> </table>		Name	Execution Date	F. Timothy Guilford	01/09/2012	Brian C. Keller	01/09/2012														
Name	Execution Date																				
F. Timothy Guilford	01/09/2012																				
Brian C. Keller	01/09/2012																				
RECEIVING PARTY DATA																					
<table border="1"> <tr> <td>Name:</td> <td>Your Energy Systems, LLC</td> </tr> <tr> <td>Street Address:</td> <td>555 Bryant St., Suite 305</td> </tr> <tr> <td>City:</td> <td>Palo Alto</td> </tr> <tr> <td>State/Country:</td> <td>CALIFORNIA</td> </tr> <tr> <td>Postal Code:</td> <td>94301</td> </tr> </table>		Name:	Your Energy Systems, LLC	Street Address:	555 Bryant St., Suite 305	City:	Palo Alto	State/Country:	CALIFORNIA	Postal Code:	94301										
Name:	Your Energy Systems, LLC																				
Street Address:	555 Bryant St., Suite 305																				
City:	Palo Alto																				
State/Country:	CALIFORNIA																				
Postal Code:	94301																				
PROPERTY NUMBERS Total: 9																					
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>11163979</td> </tr> <tr> <td>Application Number:</td> <td>60597041</td> </tr> <tr> <td>Application Number:</td> <td>60522785</td> </tr> <tr> <td>PCT Number:</td> <td>US0540308</td> </tr> <tr> <td>Application Number:</td> <td>11420168</td> </tr> <tr> <td>Application Number:</td> <td>60803474</td> </tr> <tr> <td>PCT Number:</td> <td>US0660271</td> </tr> <tr> <td>PCT Number:</td> <td>US0611397</td> </tr> <tr> <td>Application Number:</td> <td>13222254</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	11163979	Application Number:	60597041	Application Number:	60522785	PCT Number:	US0540308	Application Number:	11420168	Application Number:	60803474	PCT Number:	US0660271	PCT Number:	US0611397	Application Number:	13222254
Property Type	Number																				
Application Number:	11163979																				
Application Number:	60597041																				
Application Number:	60522785																				
PCT Number:	US0540308																				
Application Number:	11420168																				
Application Number:	60803474																				
PCT Number:	US0660271																				
PCT Number:	US0611397																				
Application Number:	13222254																				
CORRESPONDENCE DATA																					
Fax Number:	(410)649-4758																				
Phone:	4106494761																				
Email:	schummb@danmclaw.com																				

OP \$360.00 11163979

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.

Correspondent Name: Brooke Schumm III
Address Line 1: 1 N. Charles St.
Address Line 2: Suite 2450
Address Line 4: Baltimore, MARYLAND 21201

ATTORNEY DOCKET NUMBER:

GLFD

NAME OF SUBMITTER:

Brooke Schumm III

Total Attachments: 3

source=Keller-GuilfordAssignment#page1.tif

source=Keller-GuilfordAssignment#page2.tif

source=Keller-GuilfordAssignment#page3.tif

ASSIGNMENT AGREEMENT


THIS AGREEMENT, made and entered into effective this 1st day of June, 2004, between Dr. F. Timothy Guilford, M.D., ("Dr. Guilford"), Brian C. Keller, Pharm. D. ("Dr. Keller") and Your Energy Systems, LLC ("YES"), a California limited liability company,

A. Dr. Guilford is the inventor of a certain invention called "Liposomal Formulation For Oral Administration Of Glutathione (Reduced)" and requested that Dr. Keller, an officer of Biozone Laboratories, Inc., to assist him in formulating and manufacturing a liposomal form of reduced glutathione product for oral delivery. In cooperation, they designed specific formulations which Biozone Laboratories, Inc. formulates for Dr. Guilford and YES (the "Invention"). They agreed to assign the rights to the invention and any methods and other formulations stemming from that Invention to Dr. Guilford and his designee, YES. A number of Provisional applications and U.S. Patent Applications have been filed, including as set forth in Exhibit A.


NOW THEREFORE, in consideration of the mutual covenants, promises and obligations in this Agreement, and other good and valuable consideration, the parties agree as follows:

1. Dr. Guilford and Dr. Keller hereby assign to YES all of their entire right, title and interest in the entire Invention, including any improvements, patent rights, and applications, including national stage filings, divisions, continuations, and continuations-in-part, reissues, and extensions thereof and all rights of priority or benefit resulting from the filing of the U.S. application(s), both domestic and foreign, including as to divisional, continuing, and reissue applications.
2. Dr. Guilford, Dr. Keller, and YES, LLC mutually agree and request any official whose duty it is to issue patents to issue any patent on said Invention, and any improvements on or resulting therefrom to YES, its successors, assigns or nominees. Dr. Guilford and Dr. Keller agree that on request and without further consideration, but at the expense of YES for preparation of any and all papers or applications or other documents and for any other costs, they will communicate any facts known to them respecting said improvement, sign all lawful papers prepared by YES, execute all divisional, continuing, and reissue applications, and make all rightful oaths to aid the assignee and its successors, assigns and nominees to obtain and enforce proper patent protection for said invention in any country.
3. Dr. Guilford, Schumm and YES respectively agree to notify the other party promptly of any written claims or demands against the other party for which such party is responsible hereunder and to give five days notice of any default. In the event of any dispute, YES agrees to prepay for and to submit any dispute to an intellectual property attorney in the Washington, D.C. or Arlington, VA area for non-binding mediation prior to any action to enforce any breach of obligation under this Agreement, except payment obligations.

4. Brooke Schumm III and Lee Pederson, each patent attorneys, have been and are authorized to file applications and take all necessary actions to accomplish the prosecution of the patent applications. Dr. Guilford and YES are authorized to execute powers of attorney before the U.S. Patent and Trademark Office to accomplish this assignment and the applications pending pursuant to the assignment.




Dr. F. Timothy Guilford, Inventor



Dr. Brian C. Keller, Co-inventor

YOUR ENERGY SYSTEMS, LLC



F. Timothy Guilford
Its authorized agent

EXHIBIT A

U.S. Provisional Application No. 60/597,041 filed Nov. 6, 2005, and 60/522,785, filed Nov. 7, 2004, both entitled "Liposomal Formulation for Oral Administration of Glutathione (Reduced)"

U.S. Ser. No. 11/163,979 filed Nov. 6, 2005 Liposomal Formulation for Oral Administration of Glutathione (Reduced), and international applications claiming benefit from these prior applications including PCT/US05/40308.

U.S. Ser. No. 11/420,168 filed May 25, 2006 and U.S. Provisional Appl. 60/803,474 entitled "Liposomal Formulation For Oral Administration Of Glutathione (Reduced) and/or Methylcobalamine For Diseases Related To Glutathione Deficiency And Deficiency Of The Methionine Remethylation Pathway"

PCT/US06/60271 and its national entry applications, entitled "Liposomally Encapsulated Reduced Glutathione, Including With Other Pharmacologic Preparation, Capable Of Administration As An Oral, Topical, Intraoral Or Transmucosal, Preparation, For Reversal And Prevention Of Oxidation Of Cholesterol And Of Low Density Lipoprotein"

PCT/US06/11397 and its national entry applications entitled "Administration of Glutathione (Reduced) via Intravenous or Encapsulated in Liposome for Treatment of TNF-alpha Effects and Flu-Like Viral Symptoms"

U.S. Ser. No. 13/222,254 filed August 31, 2011 entitled "Liposome-Encapsulated Glutathione for Oral Administration" allowed on accelerated examination